Financial Performance - The group's revenue increased by approximately 4.5% from about HKD 67.2 million for the year ended March 31, 2020, to about HKD 70.2 million for the year ended March 31, 2021, primarily due to strong sales of the pharmacy automation system[13]. - Gross profit decreased by approximately HKD 2.8 million or 7.6% from about HKD 36.4 million for the year ended March 31, 2020, to about HKD 33.6 million for the year ended March 31, 2021, with the gross profit margin dropping from approximately 54.1% to 47.9%[14]. - Net profit decreased by approximately HKD 1.7 million from about HKD 9.6 million for the year ended March 31, 2020, to about HKD 7.9 million for the year ended March 31, 2021, mainly due to the reduction in gross profit[18]. - Administrative and other operating expenses increased by approximately HKD 1 million or 4.0% from about HKD 24.4 million for the year ended March 31, 2020, to about HKD 25.4 million for the year ended March 31, 2021, primarily due to an increase in the number of employees[15]. - The income tax expense for the year ended March 31, 2021, was approximately HKD 1.5 million, down from HKD 2.3 million in 2020[16]. - The total cash and bank balances as of March 31, 2021, were approximately HKD 70.2 million, slightly down from HKD 70.6 million in 2020[21]. - The group had no significant capital commitments or major investments as of March 31, 2021, maintaining a debt-free status with a debt-to-asset ratio of zero[22][29]. - Employee costs for the year ended March 31, 2021, were approximately HKD 15.6 million, up from HKD 14 million in 2020, with a total of 34 employees compared to 33 in the previous year[33]. Dividends and Shareholder Returns - The board declared an interim dividend of HKD 0.45 per ordinary share for the year ended March 31, 2021, compared to HKD 0.4375 per share for 2020[19]. - The dividend policy considers factors such as actual and expected financial performance, capital and debt levels, and operational funding needs[132]. - Dividends may be paid in cash or through the issuance of shares, subject to legal and regulatory compliance[134]. - The board has the discretion to decide on dividend payments based on various factors, including capital structure and future opportunities[137]. - The dividend policy is published on the company's website for investor reference[139]. Market and Product Development - The company successfully supplied Hong Kong's first pharmacy automation system, enhancing its position as a pioneer in this technology[9]. - The company remains optimistic about the healthcare sector's prospects due to the growing elderly population and increasing healthcare awareness among Hong Kong citizens[9]. - The company plans to further diversify its product portfolio and enhance customer service to improve its one-stop medical equipment solution services[12]. - The company aims to address the healthcare workforce shortage in Hong Kong through its automation solutions[9]. - The actual net proceeds from the share offering were approximately HKD 31.2 million, with a difference of HKD 1.9 million from the estimated proceeds of HKD 33.1 million disclosed in the prospectus[37]. - The group plans to utilize HKD 6.1 million for further penetration into the medical device market, with HKD 5.5 million remaining to be used by March 31, 2022[39]. - The company is focused on expanding its market presence and developing new products and technologies to enhance its competitive edge[44][52]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on enhancing user experience and engagement[75]. - Market expansion efforts include entering two new regions, which are anticipated to increase market share by 5%[75]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with a budget of up to HKD 300 million allocated for potential deals[75]. Corporate Governance and Management - The company is committed to maintaining high standards of corporate governance and compliance through its various committees[44][50]. - The board consists of six members, including the Chairperson and CEO, ensuring a balanced composition in terms of age, gender, and tenure[64]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2021[65]. - The attendance record for board meetings shows that all directors participated actively, with most attending 100% of the meetings[68]. - The company has a strong focus on risk management and internal controls, delegating daily operations and business development plans to the management team[71]. - The management team is required to obtain board approval before entering into any significant transactions or contracts[71]. - The company has maintained a high level of corporate governance, which is crucial for enhancing corporate value and accountability[60]. - The board includes independent non-executive directors, with at least one possessing appropriate professional qualifications in accounting or related financial management[71]. - The company emphasizes transparency and shareholder rights as part of its governance practices[60]. - The management team has over 20 years of experience in accounting, auditing, and financial management, contributing to the company's strategic direction[58]. - The company has established a robust investor relations strategy to communicate effectively with stakeholders[48]. - The company has established measurable goals for board member diversity and monitors progress towards achieving these goals[102]. Environmental, Social, and Governance (ESG) Initiatives - The report emphasizes the importance of integrating environmental, social, and governance (ESG) principles into the company's risk management system[141]. - The ESG report covers activities, challenges, and measures taken during the fiscal year ending March 31, 2021[146]. - Stakeholder engagement is prioritized, with communication channels established for feedback from shareholders, customers, suppliers, and regulatory bodies[148]. - Key performance indicators related to ESG are collected and reported, focusing on direct operational control within the company and its subsidiaries[143]. - The company is committed to continuous assessment and improvement of its ESG risk management and internal control systems[155]. - The report identifies significant ESG issues, including product safety, employee welfare, and regulatory compliance[155]. - The company has established a whistleblowing mechanism for stakeholders to report suspected misconduct or policy violations[158]. - The ESG report is prepared in accordance with the guidelines set forth by the Hong Kong Stock Exchange[144]. - The company aims to create greater value for the community through collaboration with stakeholders and addressing their expectations[148]. - The total greenhouse gas emissions decreased from approximately 55 tons of CO2 equivalent in FY2020 to about 45 tons in FY2021, representing a reduction of approximately 18.2%[167]. - The total paper consumption decreased from approximately 836 kg in FY2020 to about 740 kg in FY2021, a reduction of approximately 11.5%[175]. - The company has implemented various energy-saving measures to achieve its emission reduction and energy efficiency goals[162]. - The company has not reported any significant violations of environmental laws and regulations during the reporting period[167]. - Energy consumption decreased from approximately 146,139 kWh in FY2020 to about 132,563 kWh in FY2021, representing a reduction of approximately 9.3%[181]. - Total water consumption reduced from approximately 8 cubic meters in FY2020 to 3 cubic meters in FY2021, a decrease of about 62.5%[184]. - The company encourages employees to participate in activities promoting a green environment, enhancing awareness of energy management[181]. - The company has established policies to ensure fair treatment and equal opportunities for all employees, with a zero-tolerance approach to workplace harassment[199].
君百延集团(08372) - 2021 - 年度财报